@bigpharma I think you are talking about the flop of a different drug SR-9001 from Sarepta and the link to that article you mentioned is https://www.**promotion blocked**/investing/2021/01/10/heres-why-sarepta-therapeutics-lost-support-on-wal/
@SoT is absolutely correct in alerting us that Sarepta has just received FDA approval on 25.02.2021 for its AMONDYS 45 (Casimersen). Link to the FDA's official announcement is https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.035(2.70%) |
Mkt cap ! $734.9M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $2.681M | 2.075M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3081 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.11pm 28/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |